PW01-017 – Urine MMP-3 level as a biomarker for in FMF attack by unknown
MEETING ABSTRACT Open Access
PW01-017 – Urine MMP-3 level as a biomarker
for in FMF attack
B Sozeri1*, N Dincel2, E Yilmaz2, S Mir2
From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)
Lausanne, Switerland. 22-26 May 2013
Introduction
Matrix metalloproteinase-3 (MMP-3) has been implicated
in experimental and clinical models of human inflamma-
tory conditions. Increased levels of MMPs have been
shown in serum and other body fluids such as synovial
fluid in inflammatory conditions including ankylosing
spondylitis, rheumatoid arthritis and juvenile idiopathic
arthritis (JIA). Familial Mediterranean fever (FMF) is an
autosomal recessive, inherited, autoinflammatory disease
characterized by recurrent, self-limited bouts of fever and
localized inflammation, usually involving the peritoneum,
pleura, joints or skin.
Objectives
To investigate whether level of urine matrix metallopro-
teinase-3 (MMP-3) can serve as a biomarker for moni-
toring and predicting attack in patients with FMF in
daily clinical practice.
Methods
We studied 50 (28 females, 22 males) patients who diag-
nosed with FMF according to Tel Hashomer criteria and
32 healthy (21 females, 17 males) controls. We determine
all FMF subjects both in attack period (FMF-AP) and
attack free period (FMF-AFP) groups. Serum and urine
samples were obtained within the first 6–24 h of the AP,
and 10 days later after the attack (AFP). The serum sam-
ples were measured on the same day while urine samples
were collected on ice and divided into aliquots and frozen
immediately and stored at -80°C until ready for assay.
Results
The mean age at onset of symptoms was 57, 26±33.5
months. The most common symptom seen during the
attacks was: fever (n=40, 80%) abdominal pain (n=36,
72%), arthritis (n=20, 40%) and others (myalgia, erysipelas
like lesion, vasculitis, etc.) (n=6, 12%). In the genotype
distribution of patients, homozygous M694V mutation
was seen mostly (n=14, 28%). During AP, urine MMP-3
levels of patients was higher as well as during AFP and
controls (2,32±0,51 ng/mL, 0.89 ± 2,29 ng/mL and 1,24 ±
0,17 ng/mL, respectively, p=0.00). In attack period, urin-
ary MMP levels were detected higher in patients with
arthritis than others (p <0.05). In addition urinary MMP-
3 levels were significantly higher in male compared to
female patients (2, 29 ± 0,45 versus 2,24±0,57, respec-
tively, p=0,00). The patients with M694V allele (n=29)
had statistically significant high levels of urine MMP-3
levels than other patients (2.37±0,56 versus 1,99±,31,
p=0,04,respectively) . Also, acute phase reactants (WBC,
SAA, fibrinogen CRP, ESR) were higher in patients with
M694V allele but no there were no statistically significant
(p=0.89, 0.75, 0.86, 0.85, 0.7, respectively).
Conclusion
In this study we have focused on the presence and pat-
terns of appearance of MMPs in the urine of subjects with
FMF, and in healthy age-matched subjects. We showed
that inflammation-specific MMP patterns may provide
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